A comparison of three extrusion systems: Part II: The influence of formulation and spheronization conditions on pellet properties

Pharmaceutical Technology

Volumn 35, Issue 6, 2011, Pages 56-61

  Désiré, Amélie ^a   Paillard, Bruno ^b   Bougaret, Joël ^b   Baron, Michel ^a   Couarraze, Guy ^c  

^a ECOLE DES MINES D ALBI CARMAUX   (France)

^b Centre d'Immunologie Pierre Fabre   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE MATERIAL; MICROCRYSTALLINE CELLULOSE; PELLET PROPERTIES; SIZE AND SHAPE; SPHERONIZATION; STRUCTURAL AND MECHANICAL PROPERTIES; THREE SYSTEMS;

EXTRUSION; ORE PELLETS; PELLETIZING;

MECHANICAL PROPERTIES;

THEOPHYLLINE; WATER;

ARTICLE; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PELLET; DRUG SOLUBILITY; PARTICLE SIZE; PELLET EXTRUSION; PHYSICAL CHEMISTRY; SPHERONIZATION; WATER CONTENT;

EID: 80051908549     PISSN: 15432521     EISSN: 21507376     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. D. Ariely, "On Empathy and Emotion, " in Why We Respond to One Person Who Needs Help but Not to Many (HarperCollins Publishers, New York, NY, 2010), pp. 237-256.
2. Gregory Roumeliotis, "FDA Report Sheds Light on Chiron's Problems, " Outsourcing-Pharma. com, (July 2006).
3. John George, Phil. Bus. Jrnl. (January 2011).
4. R.M. Donlan, Emerg. Infect. Dis. 7 (2) 277-281 (2011).
5. J. Glausiusz, "Your Body is a Planet, " Disc. Mag. (June 2007).
6. USP 32-NF 27 General Chapter <1072>, "Disinfectants and Antiseptics" (USP, Bethesda, MD), pp. 576-580.
7. European Commission, "Medicinal Products for Human and Veterinary Use, Annex 1, Manufacture of Sterile Medicinal Products, " Rev., Guidelines to Good Manufacturing Practice (Brussels, Belgium, Nov. 2008).
8. GMP Trends #734, (GMP Trends, Inc., Boulder, CO, Aug. 15, 2007), p. 2.
9. S.S. Block, "Fundamental Principles of Activity" in Disinfection, Sterilization, and Preservation (Lippincott Williams & Wilkins, Philadelphia, PA, 5th ed., 2001), pp. 31-79.
10. GMP Trends #631 (GMP Trends, Inc., Boulder, CO, May 1, 2003), p. 4.
11. FDA, Warning Letter NEW-16-08 W, Issued Jul. 2, 2008, www. fda.gov/ICECI/EnforcementActions/WarningLetters/2008/ ucm1048221.htm, accessed Jan. 19, 2011.